MRSA Killed 700,000 Last Year-But New Treatment Created By Veteran Shows Promise AS The Next Line Of Defense-Read Article And Sign His Petition For The NIH & DOD To Do Full Testing-As We Have NO Plan B Currently!

Posted: August 5, 2015 in Deadly Disease, MRSA, Our Health, Veteran Care
Tags: , , , , , , , , ,

New Patent-Free MRSA Treatment Method And Petition For The NIH & DOD To Conduct Research On My Super-Bug Treatment Method.

I am requesting that the National Institutes of Health and Department of Defense conduct scientific research on my patent-free MRSA superbug treatment method.

Watch This Video:

Matthew Mcpherson Dublin, OH

More Deadly Than Most Realize

Last year 700,000 people died from this flesh eating disease. I have treated my last three MRSA infections with my combination treatment.

What Is MRSA?

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph that is resistant to certain antibiotics.

These antibiotics include methicillin and other [narrow-spectrum B-lactamase-resistant penicillin antibiotics] such as cloxacillin, dicloxacillin, oxacillin, and nafcillin, as well as a closely related class of drugs known as cephalosporins (e.g., cephalexin).

Overuse of antibiotics and the use of more powerful drugs than necessary for less serious infections may be some of the causes of the development of MRSA.

Approximately 1-2% of people carry MRSA on their skin or in their nose.

Infections caused by MRSA, for the most part, are not different from any other staph infection, although some strains of MRSA may be more aggressive than regular staph.

The diagnosis of a MRSA infection requires laboratory testing.

Laboratory testing can also be important since MRSA’s antibiotic resistance may make it more difficult to manage; testing can guide treatment.

The diagnosis of a MRSA infection requires laboratory testing.

Your doctor might recommend laboratory testing of a wound that looks infected and is not healing properly in order to confirm whether it is caused by MRSA and to determine which antibiotics might be useful in treating it.

Did you know MRSA kills more Americans each year than AIDS?

Methicillin-resistant Staphylococcus Aureus (MRSA) is a type of staph bacteria that is resistant to many antibiotics so is sometimes called a “superbug”.

In the community, most MRSA infections are skin infections that are minor (like a pimple, bump or boil) and can be treated with antibiotics.

However, it can quickly turn into deep, painful abscesses that require surgical draining.

Sometimes the bacteria remain confined to the skin, but they can also penetrate into the body, causing potentially life-threatening infections in bones, joints, surgical wounds, the bloodstream, heart valves and lungs. 

The vast majority of serious infections are linked to health care exposure like hospitals and nursing homes.

A few years ago the CDC and The Journal of the American Medical Association reported MRSA is killing more Americans each year than AIDS.


That year there were nearly 19,000 MRSA deaths while roughly 16,000 people in the U.S. died from AIDS.

I’m Not A Vet-How Does This Affect Me?

A USA TODAY investigation shows MRSA bacteria, once confined to hospitals, are emerging in communities to strike an increasing number of children, as well as schools, prisons, even NFL locker rooms.

Though hospitals have cut infection rates, MRSA cases among children are rising.

Most cases in communities go untracked, so government estimates undercount the threat.

MRSA can strike when the flu hits, with deadly results.

USA Today Reports: “Dangerous MRSA Bacteria To Expand Into Communities…”

Eric Allen went to bed March 1, thinking he had a light flu.

By the time he staggered into the hospital in London, Ky., the next day, he was coughing up bits of lung tissue. Within hours, organs failing, he was in a coma.

Tests showed that Allen, 39, had a ravaging pneumonia caused by methicillin-resistant Staphylococcus aureus, or MRSA, an antibiotic-resistant bacteria once confined to hospitals and other health care facilities.

Allen hadn’t been near a doctor or a hospital.

Same with the next victim, a 54-year-old man, who came in days later and died within hours.

And the victim after that, a 28-year-old woman, dead on arrival.

The doctors were alarmed.

“What really bothered me was the rapidity of their deterioration, a matter of hours,” says Muhammad Iqbal, a pulmonologist who chairs the infection control committee at Saint Joseph-London hospital.

“We were worried that something was spreading across the community.”

Indeed, a deadly form of MRSA had sprung from nowhere, picking off otherwise healthy people.

The cases thrust Iqbal and his colleagues to the front lines of modern medicine”s struggle against antibiotic resistant bacteria – perhaps the nation’s most daunting public health threat.

No drug-defying bug has proved more persistent than MRSA, none has caused more frustration and none has spread more widely.

In recent years, new MRSA strains have emerged to strike in community settings, reaching far beyond hospitals to infect schoolchildren, soldiers, prison inmates, even NFL players.

A USA TODAY examination finds that MRSA infections, particularly outside of health care facilities, are much more common than government statistics suggest.

They sicken hundreds of thousands of Americans each year in various ways, from minor skin boils to deadly pneumonia, claiming upward of 20,000 lives.

The inability to detect or track cases is confounding efforts by public health officials to develop prevention strategies and keep the bacteria from threatening vast new swaths of the population.

Not many of us have heard a lot about this, nor grasp how potentially dangerous the spread AND evolving tenacity of MRSA could be. Many of the “Successful” Antibiotics are losing potency while making MRSA more dangerous.

Superbug, Super-Fast Evolution – April 2008:

Fascination with tiny microbes bearing long, difficult-to-pronounce names is often reserved for biology classrooms — unless of course the bug in question threatens human health. 

MRSA (methicillin-resistant Staphylococcus aureus) now contributes to more US deaths than does HIV, and as its threat level has risen, so has the attention lavished on it by the media.

At this point, almost any move the bug makes is likely to show up in your local paper.

Last month saw reporting on studies of hospital screening for MRSA (which came up with conflicting results), stories on MRSA outbreaks (involving both real and false alarms), and media flurries over the finding that humans and their pets can share the infection with one another.

Why is this bug so frightening?

The answer is an evolutionary one.

Where’s the evolution?

MRSA is resistant not only to the antibiotic methicillin, but also to whole other suites of our drugs, making it very difficult to treat and, occasionally, deadly.

Modern strains of MRSA did not, however, show up out of the blue.

In the early 1940s, when penicillin was first used to treat bacterial infections, penicillin-resistant strains of S. aureus were unknown — but by the 1950s, they were common in hospitals.

Methicillin was introduced in 1961 to treat these resistant strains, and within one year, doctors had encountered methicillin-resistant S. aureus. 

Today, we have strains of MRSA that simultaneously resist a laundry list of different antibiotics, including vancomycin — often considered our last line of antibacterial defense.

How did S. aureus morph from a minor skin infection to a terror?

When the media report on MRSA and other drug resistant pathogens, they often say that such pathogens have recently “emerged” — that they’ve “developed” resistance or “learned” to evade our drugs.

In fact, it’s more accurate to say that these bugs have evolved resistance.

It’s particularly ironic that newspapers might shy away from describing bacterial evolution as such because, when it comes to evolution, bacteria have most of the rest of us beat.

Bacteria are great evolvers for many reasons.

For example, their short generation times and large population sizes boost the rate at which they can evolve. In addition, one quirk of bacterial genetics is particularly salient to the evolution of antibiotic resistance: horizontal transfer.

Evolution with vertical transmission.

In most familiar organisms, new gene variants arise in a population through random mutation — that is, one individual experiences a genetic mutation and if that mutation ups the individual’s ability to survive and reproduce, it is favored by natural selection.

Mutant gene variants are passed from parent to offspring, and advantageous mutations spread through future generations in that way.

Over time, additional beneficial mutations that build on the first may occur and begin to spread in the population, allowing more complex traits to evolve as mutations accumulate.

This standard picture of evolution is at work in all organisms — whether they are humans that eventually evolve the ability to digest milk or a plant species that adapts to the presence of heavy metals in its environment.

The same mechanism also works on bacteria. In fact, biologists have observed the MRSA strain infecting a single patient evolving through random mutation and selection.

The patient was being treated with vancomycin, and slowly, over the course of a few months and 35 separate mutations, the bacteria evolved into a vancomycin-resistant MRSA strain.

Evolution with horizontal transfer.

So bacteria acquire genetic variation through random mutation, but, unlike humans or oak trees, they also regularly get new gene variants through the process of horizontal transfer — that is, they can pass DNA back and forth to one another directly.

For example, bacterial genes can be incorporated into small self-replicating circles of DNA called plasmids, which can be “injected” into other bacteria.

The receiving bacterium may even incorporate some of the new DNA from the plasmid into its own genome and pass those genetic sequences on to its descendants.

Importantly, bacteria do not have to be closely related to share DNA. Horizontal transfer can occur across even distantly related species — which would be a bit like you picking up the family pet and winding up with a few cat genes in your genome.

In terms of evolution, this means that bacteria do not have to rely on random mutation to produce a beneficial gene variant.

One species might pick up an advantageous gene from another species, and the process of natural selection could begin to act right away, spreading the new variant through future generations.


Mr McPhersons Protocol has already had limited but successful testing, but needs the full support of Government Health and Military Health Research Facilities to enable it’s deployment into the Military Fields of Operation, where the MRSA Statistics are even higher, as well as into the American Health system, as all of our “Plan B’s” are losing ground.

The MRSA foundation, a California based medicial non-profit organization, covered my story and hosted my video on their website. I am giving away idea patent and compensation free.

About Matthew McPherson:

My name is Matthew R. McPherson.

I am a United States Veteran who invented a method to treat my reoccurring MRSA (Methicillin-resistant Staphylococcus Aureus) infections.

In the Navy I worked on phased array radar and mainframe computer systems which control the AEGIS Tomahawk cruise missile system.

Jonas Salk gave the world his polio vaccine patent-free, and I am doing the same with my MRSA treatment.

Currently I have treated two MRSA infections with my method without antibiotics.

It works by combining 1000 watt full spectrum light, alternating hot and cold air, staphaseptic mixed with Epson salt.

There is peer reviewed science why each of these ideas work.

Combining multiple peer review methods and the use of  a blue spectrum hydroponics bulb is my idea.

In the past I have had over 15 MRSA infections and have been  hospitalized in three of them.

I am not sure where I contracted my first MRSA infection.

My MRSA research was motivated by saving my life from my frequent reoccurring MRSA that was slowly killing me.

I had the puss head cultured at the VA medicial center and it came back as MRSA.

I treated it with only one session of my new light setup and no drugs of any kind.

I live in Ohio.

I have a neighbor friend who is a retired microbiologist.

He believes the idea is sound.

My medical record clearly supports the effectiveness of the MRSA treatment method.

From this point forward I am devoting my life to getting new treatments of MRSA through the FDA.

My doctor friend say it can’t be done but never underestimate the fight of this Veteran.

I am taking my treatment directly to the people through my YouTube video and future tours.

Read more about it

Primary literature:

Chambers, H. F. (2001). The changing epidemiology of Staphylococcus aureus? Emerging Infectious Diseases 7(2):178-182.

Enright, M. C., Robinson, D. A., Randle, G., Feil, E. J., Grundmann, H., and Spratt, B. G. (2002). The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proceedings of the National Academy of Sciences 99(11):7687-7692.

Ferber, D. (2003). Triple-threat microbe gained powers from another bug. Science 302(5650):1488.

Herold, B. C., Immergluck, L. C., Maranan, M. C., Lauderdale, D. S., Gaskin, R. E., Boyle-Vavra, S., Leitch, C.D, and Daum, R. S. (1998). Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Journal of the American Medical Association 279(8):593-598.

Hiramatsu, K., Cui, L., Kuroda, M., and Ito, T. (2001). The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends in Microbiology 9(10):486-493.

Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., and Tomasz, A. (2007). Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proceedings of the National Academy of Sciences 104(22):9451-9456.

Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., Kolonay, J. F., Shetty, J., Killgore, G. E., and Tenover, F. C. (2003). Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302(5650):1569-1571

Sign Matthew’s Petition:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s